Featured Research

from universities, journals, and other organizations

Chicago Researchers Testing HIV Vaccine For Healthy People

Date:
May 10, 2002
Source:
Rush Presbyterian St. Luke's Medical Center
Summary:
Infectious disease researchers at Rush-Presbyterian-St. Luke's Medical Center in Chicago have embarked on a search to find a vaccine to prevent people from contracting the human immuodeficiency virus (HIV).

Infectious disease researchers at Rush-Presbyterian-St. Luke's Medical Center in Chicago have embarked on a search to find a vaccine to prevent people from contracting the human immuodeficiency virus (HIV).

Rush is recruiting patients for a Phase I clinical trial to test the safety of an HIV vaccine that has potential to protect healthy people against the disease. This is one of two types of vaccines being tested around the world, according to infectious disease specialist Dr. Beverly Sha. Other HIV vaccine trials involve testing therapies on those already infected. Rush is the only Chicago-area medical center participating in this HIV vaccine study. Merck Pharmaceuticals is funding this phase of the study.

"I think this is the Holy Grail of HIV treatments, to prevent healthy people from getting infected," said Dr. Sha. With 15,000 new HIV infections each day, 95 percent of which occur in developing countries, there are compelling reasons to search for a vaccine, according to Sha. Existing methods of HIV prevention - abstinence, condoms and education - have not reduced the worldwide incidence of HIV.

Patients who enroll in the study will be randomly assigned to one of three regimens: one group will receive a priming vaccine at the start of their enrollment and the HIV-1 DNA gag vaccine with adjuvant aluminum phosphate; another group will receive the HIV-1 DNA gag vaccine with only the adjuvant; and a third group will receive a placebo injection. Adjuvants are substances sometimes included in a vaccine formulation to enhance or modify the immune- stimulating properties of a vaccine.

The vaccines Sha is testing work by using delivery vehicles known as vectors to transport a gene of HIV-1, known as gag into the cells. The HIV-1 gag DNA vaccine uses plasmid, or "naked" DNA as a vector. The HIV-1 gag replication-defective adenovirus vaccine is based on a modified common cold virus, altered so it cannot reproduce and cause illness. The delivery of the HIV-1 gene gag into the cells stimulates the body to generate a potent cellular immune response to HIV-1, producing an army of killer T-cells that recognize and kill HIV-1-infected cells, now and in the future.

Preliminary analysis presented at the 9th Conference of Retroviruses and Opportunistic Infections in February suggests that the HIV-1 gag vaccines for the prevention and treatment of HIV-1 elicit specific antiviral cellular immune responses and are generally well tolerated.

Sha is recruiting healthy patients between the ages 18-50 with no kidney or liver diseases and who are not pregnant. After each injection, patients will be given liver and kidney tests and a double-stranded DNA test to see if the body develops antibodies and an immune response against the DNA. Pathologists will also perform special assays to expose cells to components of the vaccine to see how well they respond.

Rush researchers will examine patients closely for local reactions to the shot, flu-like symptoms or any autoimmune response.

Sha said that if the vaccine is found safe and effective, it would be appropriate for nearly everyone as 100 percent of the population is or becomes sexually active. She indicated that this trial represents significant progress in a search for a preventive measure against HIV.

"While we don't know if this will be effective, we know that there are other sexually transmitted diseases that we have worked on much longer without reaching this point," Sha said. She indicated that patients likely to enroll in this trial are those who have a loved one or close friend who has HIV or AIDS and wants to assist in the search for an effective vaccine.

To enroll in the study, call 312/942-5865.

Rush-Presbyterian-St. Luke's Medical Center includes the 824-bed Presbyterian-St. Luke's Hospital; 110-bed Johnston R. Bowman Health Center; Rush University (Rush Medical College, College of Nursing, College of Health Sciences and the Graduate College).


Story Source:

The above story is based on materials provided by Rush Presbyterian St. Luke's Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Rush Presbyterian St. Luke's Medical Center. "Chicago Researchers Testing HIV Vaccine For Healthy People." ScienceDaily. ScienceDaily, 10 May 2002. <www.sciencedaily.com/releases/2002/05/020510074849.htm>.
Rush Presbyterian St. Luke's Medical Center. (2002, May 10). Chicago Researchers Testing HIV Vaccine For Healthy People. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2002/05/020510074849.htm
Rush Presbyterian St. Luke's Medical Center. "Chicago Researchers Testing HIV Vaccine For Healthy People." ScienceDaily. www.sciencedaily.com/releases/2002/05/020510074849.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins